TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06073782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Group
Description: . Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
Study: NCT04687462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Description: TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Description: TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Study: NCT06032728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
Study: NCT05299866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Study: NCT04795635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMM + Axon Therapy
Description: transcutaneous magnetic stimulation (tMS)
Study: NCT06473350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The application of right lateral, supine, and prone positions to preterm infants after feeding
Description: Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
Study: NCT05731115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent Pneumococcal
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent Pneumococcal
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent Pneumococcal
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
Study: NCT05588531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1:YK-1169
Description: YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1:YK-1169
Description: YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2:YK-1169/Placebo Injection
Description: YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3:YK-1169/Placebo
Description: On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 4:YK-1169/Placebo
Description: On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 5:YK-1169/Placebo Injection
Description: YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection
Description: YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
Study: NCT05475522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided brain tumor resection
Description: Surgeon intraoperatively assesses extent of tumor resection using ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5-aminolevulinic acid fluorescence-guided brain tumor resection
Description: Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
Study: NCT05859217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral once per day, Days 1 - 21 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous (IV) once every 21 days
Study: NCT05332223

Intervention type: DIAGNOSTIC_TEST
Intervention: Full Polysomnography
Description: Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
Study: NCT06183138

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study: NCT05826470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANBERG®|Thermal Therapy System
Description: Focal laser ablation.
Study: NCT05651867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIONE device
Description: The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
Study: NCT06084767

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-TCR-FAPI PET/CT
Description: A dose of 3.7 MBq/kg 68Ga-TCR-FAPI will be intravenously injected and PET examination will be carried out within the specified time.
Study: NCT06092424

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relocation from HA to LA
Description: Patients will be relocated by bus from Quito (2840m) to Pedernales (sea level) and have investigations at both altitudes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relocation from HA to LA
Description: Patients will be relocated by bus from Quito (2840m) to Pedernales (sea level) and have investigations at both altitudes
Study: NCT05043922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: a Selective PI3Kα Inhibitor
Study: NCT04893252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab and vactosertib
Description: durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
Study: NCT05059743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Larotinib
Description: Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.
Study: NCT05847673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Smoking Cessation Intervention
Description: Receive EQQUAL A intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Smoking Cessation Intervention
Description: Receive EQQUAL B intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06134635

Intervention type: DRUG
Intervention: Statins
Description: Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral

Intervention type: DRUG
Intervention: Statins
Description: Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral

Intervention type: DRUG
Intervention: Evolocumab
Description: Evolocumab 140mg twice a month, subcutaneous injection
Study: NCT04052828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
Description: This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
Study: NCT05847673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via SMS text messages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via SMS text messages
Study: NCT04669015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novaferon
Description: a novel recombinant antiviral protein drug

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation vehicle
Study: NCT05889702

Intervention type: BEHAVIORAL
Intervention: KATR Linkage Strategy
Description: The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs.
Study: NCT05013424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injection
Study: NCT04911894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI321
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study: NCT05432401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting FLT3 chimeric antigen receptor
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
Study: NCT05269745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching through immobilisation (IG)
Description: The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching through immobilisation and activity (IAG)
Description: The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).

Intervention type: OTHER
Group type: OTHER
Intervention: Control Phase
Description: Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
Study: NCT06147297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuned In
Description: The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
Study: NCT06198348

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise
Description: Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises with Resistance training
Description: These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~1. Leg press (dual leg press):~   Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~2. Crunches:~   Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~3. Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set
Study: NCT05512143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
Study: NCT06148623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
Description: Noninvasive pulse oximeter
Study: NCT06581588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE
Description: Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE combine nasopharyngeal airway
Description: Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
Study: NCT05301491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Therapy Group
Description: Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~1. Unilateral hip-knee flexion (self-assisted exercise)~2. Bilateral hip-knee flexion (self-assisted exercise)~3. Straight leg lifting with the aid of a sheet/rigid band~4. Posterior pelvic tilt~5. Bridge building exercise~6. Cat-camel exercise~7. Half shuttle in sagittal plane~8. Right and left rotational shuttle~9. Trunk hyperextension in prone position~10. Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyhsiotherapy Modalities
Description: 20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyhsiotherapy Modalities
Description: 20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
Study: NCT04721613

Intervention type: OTHER
Intervention: Assessment of Melatonin level
Description: Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.

Intervention type: OTHER
Intervention: Assessment of Melatonin level
Description: Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.

Intervention type: OTHER
Intervention: Assessment of Melatonin level
Description: Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
Study: NCT05084859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel to be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI Protocol to be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab to be administered intravenously.
Study: NCT05985785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate concentrate (BMAC)
Description: Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injections
Description: Current standard of treatment for OA of the knee is corticosteroid injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Crossover Autologous bone marrow aspirate concentrate (BMAC)
Description: Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
Study: NCT04723238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg Test Drug Enteric Coated Granules
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg Reference Product Enteric Coated Granules
Description: Cymbalta (Eli Lilly)